Cryo-Cell International Inc (CCEL)
XASE:CCEL
Want to see CCEL full AI Analyst Report?
Top Page
Cryo-Cell International
(NYSE MKT:CCEL)
Select Model
Select Model
Rating:46Neutral
Price Target:
$3.50
▼(-14.43% Downside)
Action:ReiteratedDate:04/15/26
The score is primarily held back by weak financial fundamentals—especially negative equity—reinforced by the NYSE listing compliance risk. Technicals provide some near-term support, and the high dividend yield helps valuation, but the very high P/E and unstable profitability limit the overall rating.
Positive Factors
Strong gross margins
Sustained mid-70% gross margins indicate durable unit economics for cord blood/tissue processing and storage. High gross margins support long-term cash generation from each customer even if revenue growth is slow, enabling reinvestment in lab capabilities and margin resilience over cycles.
Negative Factors
Negative stockholders' equity
A persistent stockholders' deficit materially weakens the balance sheet, limiting financial flexibility and increasing funding and covenant risks. Negative equity is a structural constraint that can restrict access to credit, raise borrowing costs, and force dilutive remedies or asset sales to restore solvency.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong gross margins
Sustained mid-70% gross margins indicate durable unit economics for cord blood/tissue processing and storage. High gross margins support long-term cash generation from each customer even if revenue growth is slow, enabling reinvestment in lab capabilities and margin resilience over cycles.
Read all positive factors
Cryo-Cell International (CCEL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$28.35M
Dividend Yield11.14%
Average Volume (3M)4.07K
Price to Earnings (P/E)145.3
Beta (1Y)0.06
Revenue Growth-2.56%
EPS Growth-2181.76%
CountryUS
Employees82
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.01
Shares Outstanding8,055,150
10 Day Avg. Volume4,683
30 Day Avg. Volume4,066
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.73
Price to Sales (P/S)1.02
P/FCF Ratio6.12
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue0.98
Enterprise Value/Gross Profit1.26
Enterprise Value/Ebitda-2.33K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.08
Revenue Forecast (FY)$30.30M
Cryo-Cell International Business Overview & Revenue Model
Company Description
Cryo-Cell International (CCEL) is a leading biotechnology company specializing in the collection, processing, and storage of stem cells derived from umbilical cord blood and tissue. Founded in 1992, CCEL operates primarily in the regenerative medi...
How the Company Makes Money
Cryo-Cell primarily makes money by charging customers for newborn stem cell banking services and related fees over the life of a storage contract. Key revenue streams typically include: (1) upfront service fees for the collection kit and laborator...
Cryo-Cell International Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
22
Negative
Cash Flow
58
Neutral
| Breakdown | TTM | Nov 2025 | Feb 2025 | Nov 2023 | Feb 2023 | Nov 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.28M | 31.57M | 31.99M | 31.34M | 30.34M | 28.88M |
| Gross Profit | 24.23M | 24.19M | 24.04M | 22.90M | 21.54M | 19.90M |
| EBITDA | -13.08K | 480.58K | 1.42M | -10.42M | 6.65M | 5.32M |
| Net Income | -2.67M | -2.43M | 402.10K | -9.52M | 2.77M | 2.08M |
Balance Sheet | ||||||
| Total Assets | 60.88M | 61.73M | 64.68M | 61.22M | 64.89M | 60.66M |
| Cash, Cash Equivalents and Short-Term Investments | 2.90M | 3.30M | 3.50M | 980.25K | 1.72M | 8.34M |
| Total Debt | 2.40M | 3.20M | 12.93M | 10.90M | 11.61M | 2.82M |
| Total Liabilities | 79.29M | 80.33M | 77.89M | 72.25M | 66.41M | 56.48M |
| Stockholders Equity | -18.40M | -18.61M | -13.22M | -11.03M | -1.52M | 4.18M |
Cash Flow | ||||||
| Free Cash Flow | 4.94M | 5.25M | 3.61M | 1.28M | -8.60M | 974.92K |
| Operating Cash Flow | 5.18M | 5.48M | 6.01M | 8.92M | 8.57M | 7.93M |
| Investing Cash Flow | -668.74K | -975.33K | -4.88M | -8.14M | -15.28M | -6.95M |
| Financing Cash Flow | -4.48M | -4.75M | -979.12K | -2.07M | 147.86K | -3.07M |
Cryo-Cell International Technical Analysis
Negative
4.09
Price Trends
3.34
Positive
3.50
Negative
4.05
Negative
Market Momentum
0.09
Negative
49.87
Neutral
36.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCEL, the sentiment is Negative. The current price of 4.09 is above the 20-day moving average (MA) of 3.44, above the 50-day MA of 3.34, and above the 200-day MA of 4.05, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 49.87 is Neutral, neither overbought nor oversold. The STOCH value of 36.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCEL.
Cryo-Cell International Risk Analysis
Cryo-Cell International disclosed 38 risk factors in its most recent earnings report. Cryo-Cell International reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cryo-Cell International Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $69.85M | -0.16 | -71.45% | ― | -47.74% | -1056.93% | |
46 Neutral | $28.35M | 145.34 | 15.82% | 11.14% | -2.56% | -2181.76% | |
45 Neutral | $20.20M | -0.04 | -257.39% | ― | -2.76% | -1.22% | |
44 Neutral | $8.85M | -5.59 | -8.75% | ― | -0.91% | -168.54% | |
44 Neutral | $16.72M | -0.11 | ― | ― | -22.38% | 56.66% |
* Healthcare Sector Average
CCEL
Cryo-Cell International
3.52
-1.58
-30.97%
AMS
American Shared Hospital Services
1.34
-1.36
-50.37%
CCM
Concord Medical Services
3.85
-4.66
-54.76%
DCGO
DocGo
0.71
-1.52
-68.30%
PIII
P3 Health Partners
2.80
-6.19
-68.85%
Cryo-Cell International Corporate Events
Delistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Cryo-Cell Faces NYSE American Listing Compliance Challenges
Negative
Mar 12, 2026
On March 9, 2026, Cryo-Cell International, Inc. received notice from NYSE American that it was not in compliance with continued listing standards due to a stockholders’ deficit as of Nov. 30, 2025 and net losses in two of its three most rece...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.